Comparative Pharmacology
Head-to-head clinical analysis: LORATADINE versus NEOTRIZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORATADINE versus NEOTRIZINE.
LORATADINE vs NEOTRIZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonist activity. It inhibits histamine-induced vasodilation and bronchoconstriction.
Neotrizine contains sulfadiazine, a competitive inhibitor of dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
10 mg orally once daily
NEOTRIZINE (sulfamethoxazole/trimethoprim) 800 mg/160 mg orally every 12 hours for 5-14 days, depending on indication.
None Documented
None Documented
Loratadine: 8-14 hours (mean ~10 hours). Active metabolite descarboethoxyloratadine: 17-24 hours (mean ~20 hours). Clinically, duration supports once-daily dosing.
Clinical Note
moderateLoratadine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Loratadine is combined with Fluticasone propionate."
Clinical Note
moderateLoratadine + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Sulfisoxazole
Terminal elimination half-life is 4-6 hours in adults with normal renal function; in renal impairment, half-life may extend to 12-18 hours requiring dose adjustment.
Approximately 40% excreted in urine as metabolites (primarily descarboethoxyloratadine) and 40% in feces as metabolites; <1% excreted unchanged.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal elimination accounts for 20-30%, with the remainder as metabolites.
Category A/B
Category C
Antihistamine
Antihistamine
"The metabolism of Sulfisoxazole can be decreased when combined with Loratadine."